Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Capital Leases: 2010-2014

Historic Capital Leases for Ligand Pharmaceuticals (LGND) over the last 5 years, with Dec 2014 value amounting to $934,000.

  • Ligand Pharmaceuticals' Capital Leases fell 85.63% to $228,000 in Q2 2015 from the same period last year, while for Jun 2015 it was $228,000, marking a year-over-year decrease of 85.63%. This contributed to the annual value of $934,000 for FY2014, which is 69.59% down from last year.
  • As of FY2014, Ligand Pharmaceuticals' Capital Leases stood at $934,000, which was down 69.59% from $3.1 million recorded in FY2013.
  • In the past 5 years, Ligand Pharmaceuticals' Capital Leases ranged from a high of $11.1 million in FY2010 and a low of $934,000 during FY2014.
  • In the last 3 years, Ligand Pharmaceuticals' Capital Leases had a median value of $3.1 million in 2013 and averaged $3.3 million.
  • Data for Ligand Pharmaceuticals' Capital Leases shows a maximum YoY plummeted of 69.59% (in 2014) over the last 5 years.
  • Ligand Pharmaceuticals' Capital Leases (Yearly) stood at $11.1 million in 2010, then fell by 24.74% to $8.4 million in 2011, then dropped by 28.73% to $6.0 million in 2012, then tumbled by 48.50% to $3.1 million in 2013, then plummeted by 69.59% to $934,000 in 2014.